Tag: diabetic cardiomyopathy

MicroRNAs Have an Immunomodulatory Role in Diabetes Mellitus and Diabetic Cardiomyopathy

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM), an independent diabetes complication, is characterized by abnormalities in myocardial structure, function, and metabolism, including diminished myocardial contractility, myocardial hypertrophy, and fibrosis. Factors such as hyperglycemia, metabolic disorders, microangiopathy, inflammation, oxidative stress, and insulin resistance have been found to play important roles in DCM pathophysiology.

Recent research has shown that miRNAs are involved in processes such as myocardial cell proliferation, differentiation, and metastasis, and promote the progression of DCM. Despite these insights, the regulatory effects of miRNAs on immune function in DCM remain inadequately explored.

(more…)

Loading

Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy is a multifaceted complication of diabetes that lacks effective treatments. Berberine (BBR), a bioactive compound from Rhizoma coptidis, has potential therapeutic implications, but its precise role in diabetic cardiomyopathy remains to be defined.

In this study, a diabetic cardiomyopathy model was established by administration of a high-fat diet and streptozotocin injection to C57BL/6J mice. Concurrently, the mice received BBR treatment daily for a duration of 8 weeks. After the treatment period, myocardial injury, cardiac function, and the levels of oxidative stress and apoptosis were assessed.

BBR significantly ameliorated cardiac dysfunction and histopathological damage caused by diabetic cardiomyopathy. This treatment also elevated serum superoxide dismutase levels while decreasing malondialdehyde levels. The anti-apoptotic activity of BBR was evidenced by a decrease in TUNEL-positive cells and the percentage of apoptotic cells, as determined by flow cytometry, in conjunction with diminished levels of BCL2-associated X protein/B cell lymphoma 2 (BAX/BCL2) in heart tissues. Mechanistically, BBR was found to ameliorate diabetic cardiomyopathy by upregulating the expression of myocardial methionine sulfoxide reductase A (MsrA) and concurrently suppressing cardiac CaMKII oxidation.

BBR alleviates diabetic cardiomyopathy by inhibiting myocardial apoptosis and oxidative stress through the MsrA and CaMKII signaling pathways.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0064

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xiaoqiang Sun, Zhuqing Li and Li Wang et al. Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0064

Loading